Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
SiriusPoint Ltd
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from SiriusPoint Ltd's 2026 annual general meeting held on May 20, 2026, covering four proposals: election of two Class I directors, advisory approval of named executive officer compensation, appointment of PricewaterhouseCoopers LLP as independent auditor, and approval of the SiriusPoint SharePlan. The tabulated voting results for each proposal are presented with vote counts (For, Against, Abstain, Broker Non-Votes), which is the hallmark of Item 5.07 disclosure and the shareholder_vote_results event type.
View raw filing on EDGAR →
Sprouts Farmers Market, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Sprouts Farmers Market's May 20, 2026 annual meeting. The filing presents final voting tallies for four proposals: election of two Class I directors (Joel D. Anderson and Terri Funk Graham both duly elected), advisory approval of named executive officer compensation (approved), say-on-frequency vote (one year prevailed), and ratification of PricewaterhouseCoopers LLP as auditor (approved). All proposals passed with substantial majorities, making this a material governance event that investors rely upon to assess board composition and compensation oversight.
View raw filing on EDGAR →
Rexford Industrial Realty, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from the Company's Annual Meeting of Stockholders held on May 19, 2026, covering four proposals: election of seven directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Fourth Amended and Restated 2013 Incentive Award Plan. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures and is material to investors assessing corporate governance and executive compensation matters.
View raw filing on EDGAR →
CONSTELLIUM SE
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 disclosure presents the complete voting results from Constellium SE's Annual General Meeting of Shareholders held on May 21, 2026, covering 16 proposals including director appointments (Ingrid Joerg and John Ormerod), advisory compensation votes, financial statement approvals, and share repurchase authorizations. The detailed tabulation of votes cast for, against, and abstained on each proposal is the hallmark of shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
EVERTEC, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from EVERTEC's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing presents detailed voting tallies for three proposals: election of ten directors, an advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07, and the outcomes are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
FIRST COMMUNITY CORP /SC/
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from First Community Corporation's annual meeting held May 20, 2026. The filing reports voting outcomes on three matters: election of nine directors across three classes, an advisory say-on-pay vote, and ratification of Elliott Davis, LLC as independent auditor. The detailed vote tallies (For, Against, Withheld, Broker Non-Vote) for each director candidate and proposal are the hallmark of Item 5.07 disclosure and are material to investors assessing board composition and governance.
View raw filing on EDGAR →
BBCMS Mortgage Trust 2026-5C41
Other material
confidence 75%
filed 2026-05-21
Item 8.01
This Item 8.01 discloses the issuance and sale of approximately $472.9 million in commercial mortgage pass-through certificates by BBCMS Mortgage Trust 2026-5C41, a securitization vehicle. While the filing describes the transaction structure, underwriters, and credit risk retention compliance under Regulation RR, it does not fit neatly into the standard 8-K event taxonomy (e.g., not an earnings release, M&A activity, restatement, or going-concern disclosure). The transaction is material to investors in the certificates and the registrant's stakeholders, but the disclosure is primarily informational about a completed securitization closing rather than a discrete corporate event triggering a specific Item category.
View raw filing on EDGAR →
Voya Financial, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 filing discloses the results of Voya Financial's Annual Meeting of Stockholders held on May 21, 2026, including three matters voted upon: election of twelve directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The tabulated voting results for each matter are presented with vote counts (For, Against, Abstentions, and Broker Non-Votes), which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
BankUnited, Inc.
Exec Compensation
confidence 95%
filed 2026-05-21
Item 5.02
The disclosure centers on shareholder approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan, which is a compensatory arrangement for officers and directors. The filing details the plan's material terms, including an increase of 1,500,000 shares available for equity-based awards and an extension of the termination date to 2036. This is a classic Item 5.02(e) disclosure of a compensation plan amendment approved by shareholders.
View raw filing on EDGAR →
BankUnited, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from BankUnited's Annual Meeting held May 21, 2026. The filing presents detailed voting tallies for four proposals: election of nine directors, ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan. All proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and executive accountability.
View raw filing on EDGAR →
Summit Hotel Properties, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from Summit Hotel Properties' Annual Meeting of Stockholders held on May 20, 2026. The filing reports the outcomes of three proposals: election of eight directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, and the detailed voting tallies (For/Against/Abstain/Broker Non-Votes) are provided for each matter, which is the hallmark of Item 5.07 disclosure.
View raw filing on EDGAR →
Immix Biopharma, Inc.
Dilutive issuance
confidence 95%
filed 2026-05-21
The filing discloses an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, with expected net proceeds of approximately $140.65 million. This is a material dilutive equity issuance that would significantly affect existing shareholders' ownership percentages and is disclosed under Item 8.01 (Other Events) with an underwriting agreement and prospectus supplement filed pursuant to Rule 424(b)(5).
View raw filing on EDGAR →
SharonAI Holdings Inc.
Dilutive issuance
confidence 75%
filed 2026-05-21
SharonAI Holdings issued $350 million of 6.00% Convertible Senior Notes due 2031 to qualified institutional buyers on May 18, 2026. The Notes are convertible into up to 8.7 million shares of Common Stock (or 11.3 million if accrued interest is converted), representing a significant dilutive issuance. While this is technically a debt offering, the convertible feature and the substantial equity dilution potential (conversion price of $48.24 per share, approximately 20% premium to Nasdaq Minimum Price) make this a material capital-raising event with substantial dilution implications for existing shareholders.
View raw filing on EDGAR →
Algorhythm Holdings, Inc.
Delisting risk
confidence 95%
filed 2026-05-21
The filing discloses that Algorhythm Holdings received a Nasdaq delisting notice on November 28, 2025 for failing to maintain the required $2.5 million stockholders' equity under Listing Rule 5550(b)(1), and while the company claims to have regained compliance as of March 31, 2026, Nasdaq explicitly warned that "if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01.
View raw filing on EDGAR →
Jet.AI Inc.
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The filing discloses amendments to employment agreements for Michael Winston (Executive Chairman and Interim CEO) and George Murnane (Interim CFO) that materially modify their compensatory arrangements and restrictive covenants. The amendments extend non-compete and non-solicitation periods from one to two years, introduce a new clawback provision for incentive-based compensation and bonuses, and provide $1,000 one-time bonuses in exchange for covenant compliance. These modifications to executive compensation terms and incentive structures are the principal disclosed action, making this an exec_compensation event rather than a departure or appointment.
View raw filing on EDGAR →
HCW Biologics Inc.
Dilutive issuance
confidence 95%
filed 2026-05-21
HCW Biologics disclosed entry into a Securities Purchase Agreement on May 21, 2026, for the unregistered sale of 2,846,975 units comprising common shares, pre-funded warrants, and common warrants, raising approximately $4.0 million in gross proceeds. The filing explicitly invokes Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), with securities issued under Section 4(a)(2) and Regulation D Rule 506(b). This is a classic private placement (PIPE-like) dilutive issuance to accredited investors.
View raw filing on EDGAR →
ARC Group Acquisition I Corp.
Other material
confidence 65%
filed 2026-05-21
The filing discloses that ARC Group Acquisition I Corp announced the commencement of separate trading of its unit components (Class A ordinary shares, warrants, and rights) on NASDAQ effective May 28, 2026. This is a structural capital markets event following the company's recent IPO completion (May 5-7, 2026), but does not fit neatly into the standard taxonomy categories. While material to investors as it affects trading mechanics and liquidity of the company's securities, it is neither an earnings release, executive change, M&A activity, nor a financial restatement or impairment.
View raw filing on EDGAR →
Glimpse Group, Inc.
Exec departure
confidence 92%
filed 2026-05-21
The filing discloses the resignations of three senior executives effective immediately or June 15, 2026: Lyron Bentovim (CEO and Board Chair), Maydan Rothblum (CFO, COO, Secretary, Treasurer), and Jeff Enslin (Director). The departure of the CEO and CFO represents a material change in executive leadership that would affect a reasonable investor's assessment of the company. While the filing also mentions expected appointments (Tyler Gates as CEO), the principal disclosed action centers on the departures of key officers.
View raw filing on EDGAR →
ADDENTAX GROUP CORP.
M&A activity
confidence 92%
filed 2026-05-21
The filing discloses entry into a Share Exchange Agreement on May 15, 2026, whereby the Company's subsidiary Yingxi acquires 41.67% equity interest in Riches Family Office Limited in exchange for issuance of 33,500 common shares to the Company's Chief Operating Officer. This constitutes a material acquisition activity under Item 1.01, with related-party transaction approval by the audit committee and board. The transaction involves a valuation report and is subject to Nasdaq listing notification, indicating materiality to investors.
View raw filing on EDGAR →
Wellgistics Health, Inc.
Other material
confidence 65%
filed 2026-05-21
The filing discloses a shareholder letter regarding "strategy overview and business update" under Item 8.01 (Other Events). Without access to the actual letter content (Exhibit 99.1), the materiality and specific nature of the update cannot be determined with certainty. However, a formal shareholder letter on strategy and business update filed via 8-K suggests material developments that would affect investor assessment, warranting classification as other_material rather than a more specific event type.
View raw filing on EDGAR →
Global Interactive Technologies, Inc.
Exec appointment
confidence 95%
filed 2026-05-21
The filing discloses the Board's appointment of Taehoon Kim, the current CEO, to the additional roles of Principal Financial Officer and Principal Accounting Officer, effective immediately on May 18, 2026. This is a material executive appointment that consolidates critical financial and accounting oversight functions under the CEO following the previously announced resignation of CFO Juhyon Shin. The appointment of a principal financial officer is a material event affecting investor assessment of the company's financial governance and leadership structure.
View raw filing on EDGAR →
Ocean Power Technologies, Inc.
Other material
confidence 65%
filed 2026-05-21
The filing discloses under Item 8.01 (Other Events) that Ocean Power Technologies announced an expansion in its global deployment footprint across U.S. government, international, and research customers via press release. While the specific details of the expansion are not provided in the 8-K body itself, the announcement of expanded deployment across government and international customers could be material to investors assessing the company's growth trajectory and market reach. However, without the full press release text, the precise materiality and nature of the event cannot be definitively categorized into a more specific event type, warranting classification as other_material.
View raw filing on EDGAR →
Odysight.ai Inc.
Exec appointment
confidence 85%
filed 2026-05-21
The filing discloses the appointment of Ronen Tanami as Chief Operating Officer on May 13, 2026, which is the principal action reported. While the Item 5.02 disclosure also includes compensatory details (a 40,000-share option grant), the core event is the executive appointment. The appointment of a COO is material to investors as it reflects a significant change in the company's management structure.
View raw filing on EDGAR →
STEVEN MADDEN, LTD.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from Steven Madden's 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing reports the final voting tallies for three proposals: election of ten directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote counts (For, Against, Withheld, Abstentions, Broker Non-Votes) for each proposal are the hallmark of Item 5.07 disclosures and constitute material information about corporate governance outcomes.
View raw filing on EDGAR →
I-ON Digital Corp.
Earnings release
confidence 95%
filed 2026-05-21
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition), with I-ON Digital Corp. issuing a press release on May 21, 2026 announcing financial results for the first quarter ended March 31, 2026. The press release is attached as Exhibit 99.1. This is a standard earnings release disclosure that would materially affect a reasonable investor's assessment of the registrant's financial performance.
View raw filing on EDGAR →
AIM ImmunoTech Inc.
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
Item 3.02 discloses an unregistered private placement of Common Warrants and Placement Agent Warrants under Section 4(a)(2) and Rule 506, with underlying Common Warrant Shares and shares underlying the Placement Agent Warrants. This is a classic dilutive equity issuance to accredited investors that would materially affect shareholder ownership and is a strong signal of capital-raising activity typical of smaller-cap issuers.
View raw filing on EDGAR →
AIM ImmunoTech Inc.
Dilutive issuance
confidence 85%
filed 2026-05-21
Item 8.01
The filing discloses pricing of securities offerings with exhibits including a Securities Purchase Agreement, Common Warrants, and Placement Agent Warrants dated May 20, 2026. The press release announcement of "the pricing of the Offerings" combined with warrant issuances and the securities purchase agreement structure indicates a dilutive equity issuance, likely a private placement or PIPE transaction. This is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →
LANDMARK BANCORP INC
Shareholder vote
confidence 95%
filed 2026-05-21
The filing discloses Item 5.07 results from Landmark Bancorp's Annual Meeting of Stockholders held May 20, 2026, including voting outcomes on three proposals: election of three Class I directors (Angela S. Hurt, David H. Snapp, and Angelia K. Stanland), approval of an amendment to increase authorized common shares from 7.5M to 10M, and ratification of Forvis Mazars, LLP as independent auditor. These are standard shareholder vote results that materially affect corporate governance and capital structure.
View raw filing on EDGAR →
JUPITER NEUROSCIENCES, INC.
Dilutive issuance
confidence 95%
filed 2026-05-21
Jupiter Neurosciences entered into a Securities Purchase Agreement on May 20, 2026, to issue 7,142,858 shares of common stock at $0.28 per share in a registered direct offering, raising approximately $2.0 million in gross proceeds. This is a registered equity issuance that will dilute existing shareholders and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
Co-Diagnostics, Inc.
Dilutive issuance
confidence 95%
filed 2026-05-21
Co-Diagnostics entered into a private placement on May 19, 2026, issuing 54,915 shares of common stock, 1,592,532 pre-funded warrants, and 3,294,894 common warrants for aggregate gross proceeds of $3.0 million. The filing explicitly discloses the Securities Purchase Agreement with institutional and accredited investors, detailed warrant terms, and registration rights obligations. This is a classic dilutive equity issuance (PIPE-like structure with warrants) that materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →
Wellgistics Health, Inc.
M&A activity
confidence 92%
filed 2026-05-21
The filing discloses entry into a Fully Binding Letter of Intent (Term Sheet) dated May 20, 2026, involving a material multi-party transaction. The Company would acquire or license intellectual property from EOS and SCLX, expand its Datavault license, and acquire a controlling interest in Health Lives Here from HBA. Upon conversion of Acquisition Preferred, the transaction parties would own approximately 89.6% of the Company's common stock, representing a substantial change of control. The proposed combined entity valuation is stated at $4.0 billion. While subject to definitive agreements and conditions, this constitutes entry into a material definitive agreement for M&A activity under Item 1.01.
View raw filing on EDGAR →
Immix Biopharma, Inc.
Other material
confidence 72%
filed 2026-05-21
The filing discloses interim clinical trial results from the Phase 2 NEXICART-2 trial showing that all four MRD-negative relapsed/refractory AL Amyloidosis patients have converted to complete response (CR), with a 95% CR rate (19/20) across the first 20 patients and no relapses observed. While this is positive clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard event taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, M&A activity, or executive change. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, but the event is best classified as other_material given the clinical-trial-update nature of the announcement.
View raw filing on EDGAR →
VIDA Global Inc.
Other material
confidence 65%
filed 2026-05-21
The filing discloses announcement of tokenized equity listing on xStocks via press release (Exhibit 99.1), filed under Item 7.01 (Regulation FD Disclosure). This represents a material corporate development—the introduction of a blockchain-based equity instrument—that does not fit cleanly into standard 8-K categories (not M&A, not earnings, not an executive change). The tokenization of equity is a novel capital structure event that would affect investor assessment of the company's business model and equity structure.
View raw filing on EDGAR →
Snail, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-21
The filing discloses an amendment to an at-the-market (ATM) offering program increasing capacity to $3,660,000 of Class A Common Stock shares. This is a dilutive equity issuance mechanism that provides the company with ongoing access to capital markets. The company has already sold $4,367,863 of shares under the prior ATM prospectus supplement, demonstrating active use of this dilutive financing vehicle.
View raw filing on EDGAR →
Edible Garden AG Inc
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
The Company exchanged 1,222 shares of Series B Preferred Stock (stated value $1,222,000) for 3,253,455 shares of common stock in an unregistered transaction under Section 3(a)(9) of the Securities Act. This is a material dilutive issuance of over 3.2 million common shares, which would significantly impact existing shareholders' ownership percentages and is precisely the type of equity capital raise that Item 3.02 is designed to capture.
View raw filing on EDGAR →
GlobalTech Corp
Earnings release
confidence 95%
filed 2026-05-21
Item 2.02
GlobalTech Corporation issued a press release on May 21, 2026 disclosing financial results for the quarter ended March 31, 2026, furnished as Exhibit 99.1 to the Form 8-K under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides key financial performance metrics.
View raw filing on EDGAR →
Teladoc Health, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing presents voting outcomes for three proposals: election of nine directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder voting results, and the material outcomes (all proposals passed with substantial majorities) are directly relevant to investor assessment of governance and management accountability.
View raw filing on EDGAR →
Rent the Runway, Inc.
Exec departure
confidence 95%
filed 2026-05-21
Item 5.02
Siddharth Thacker, Chief Financial Officer of Rent the Runway, Inc., tendered his resignation effective June 3, 2026. The disclosure centers on the departure of a named executive officer from a key financial leadership position, with no appointment of a successor mentioned. This is a material event affecting investor assessment of the company's financial leadership continuity.
View raw filing on EDGAR →
Rent the Runway, Inc.
Other material
confidence 65%
filed 2026-05-21
Item 7.01
The Item 7.01 disclosure reaffirms FY2026 guidance and references an ongoing CEO and CFO search process with risks of "regrettable attrition" and Board transition. While the primary action disclosed is guidance reaffirmation (routine), the forward-looking statements emphasize material risks tied to executive leadership transitions and management continuity. The filing does not explicitly disclose a specific departure or appointment, but the emphasis on search processes and transition risks suggests underlying executive changes that may be material to investors assessing management stability.
View raw filing on EDGAR →
Travere Therapeutics, Inc.
Exec Compensation
confidence 85%
filed 2026-05-21
Item 5.02
The disclosure centers on stockholder approval of an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves approval of a material equity plan amendment that affects the pool of shares available for executive and employee compensation grants. While shareholder vote results are also mentioned, the substantive focus is on the equity plan amendment itself.
View raw filing on EDGAR →
Travere Therapeutics, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Travere Therapeutics' May 19, 2026 Annual Meeting. The filing presents final voting tallies for five proposals: election of ten directors, approval of the 2018 Equity Incentive Plan amendment, advisory approval of named executive officer compensation, advisory frequency vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
TANDEM DIABETES CARE INC
Other material
confidence 75%
filed 2026-05-21
Item 3.03
The filing discloses stockholder-approved amendments to the Certificate of Incorporation that materially modify shareholder rights and governance protections, including removal of directors with or without cause and limitation of officer liability. While this is a governance matter affecting the rights of security holders, it does not fit neatly into the more specific event categories (it is not a shareholder vote result per se, but rather the implementation of amendments approved at a shareholder meeting). The amendments are material to investors as they alter fundamental governance and liability protections, warranting disclosure under Item 3.03.
View raw filing on EDGAR →
TANDEM DIABETES CARE INC
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The disclosure reports stockholder approval of an amendment to the 2023 Long-Term Incentive Plan increasing authorized shares by 3,260,000 shares. This is a compensatory arrangement affecting equity grants and incentive compensation for officers and directors, fitting the exec_compensation category. The material increase in share authorization and shareholder approval make this material to investors assessing dilution and executive compensation capacity.
View raw filing on EDGAR →
TANDEM DIABETES CARE INC
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from the May 20, 2026 Annual Meeting. The filing presents final voting tallies for six proposals: election of nine directors, advisory vote on named executive officer compensation, approval of an amended equity plan, amendments to the Certificate of Incorporation regarding director removal and officer liability, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with substantial majorities, making this a material disclosure of shareholder actions that affects the composition and governance of the company.
View raw filing on EDGAR →
NATIONAL PRESTO INDUSTRIES INC
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from the Company's Annual Meeting of Stockholders held on May 19, 2026. The filing reports the final voting tallies for three proposals: election of directors (Lieble and Stienessen), ratification of RSM US LLP as independent auditor, and advisory vote on executive compensation. This is a textbook Item 5.07 disclosure and is material to investors as it documents stockholder approval of key governance matters.
View raw filing on EDGAR →
DiaMedica Therapeutics Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from DiaMedica's 2026 Annual General Meeting held on May 20, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: director elections, auditor ratification, advisory executive compensation approval, and an omnibus incentive plan amendment. All proposals passed, and the detailed vote counts are material to investors assessing board composition, audit oversight, and equity dilution.
View raw filing on EDGAR →
Apyx Medical Corp
Other material
confidence 65%
filed 2026-05-21
Item 8.01
Apyx Medical announced publication of clinical data in a peer-reviewed journal (Aesthetic Surgery Journal Open Forum) demonstrating efficacy for cellulite and skin laxity treatment. While this is a positive clinical validation event relevant to the company's product portfolio and market positioning, it does not fit neatly into the more specific event categories (not earnings, M&A, litigation, impairment, etc.). The disclosure is material to investors assessing the company's clinical evidence base and competitive standing in aesthetic medicine, but the ambiguity about whether this constitutes a "material" event versus routine clinical publication reporting warrants moderate confidence.
View raw filing on EDGAR →
ECB Bancorp, Inc. /MD/
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from ECB Bancorp's annual meeting held May 20, 2026, reporting the election of directors (Joseph Sachetta and Susan Sgroi) and ratification of Wolf & Company, P.C. as independent auditor. Item 5.07 explicitly requires disclosure of voting results, and director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.
View raw filing on EDGAR →
Aterian, Inc.
Delisting risk
confidence 85%
filed 2026-05-21
Item 8.01
The filing discloses a delisting risk event: Aterian received a Nasdaq notice on December 9, 2025 that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day cure period. Although the company subsequently regained compliance by May 19, 2026, the core event disclosed is the delisting notice and the company's status relative to continued listing standards. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
Skyline Bankshares, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder meeting results under Item 5.07, reporting the voting outcomes for two proposals: (1) election of fifteen directors with detailed vote tallies for each nominee, and (2) ratification of Elliott Davis, PLLC as independent auditor. The filing presents the formal voting results from the May 19, 2026 Annual Meeting of Shareholders.
View raw filing on EDGAR →